Evidence map›Paper›PMID 27143556›Full record

ArticleAmerican journal of physiology. Endocrinology and metabolism2016

Glucocorticoid antagonism limits adiposity rebound and glucose intolerance in young male rats following the cessation of daily exercise and caloric restriction.

Trevor Teich, Emily C Dunford, Deanna P Porras, Jacklyn A Pivovarov, Jacqueline L Beaudry, Hazel Hunt, Joseph K Belanoff, Michael C Riddell

Open access · bronzeAbstract read
In one paragraph

Article in American journal of physiology. Endocrinology and metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Hypothalamus-pituitary-adrenal Axis in Glucolipid metabolic disorders.Reviews in endocrine & metabolic disorders · 2020
    Review
  3. Resetting the Stress System with a Mifepristone Challenge.Cellular and molecular neurobiology · 2019
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Trevor TeichMuscle Health Research Centre, School of Kinesiology and Health Science, York University, Toronto, Ontario, Canada;
Emily C DunfordMuscle Health Research Centre, School of Kinesiology and Health Science, York University, Toronto, Ontario, Canada;
Deanna P PorrasMuscle Health Research Centre, School of Kinesiology and Health Science, York University, Toronto, Ontario, Canada;
Jacklyn A PivovarovMuscle Health Research Centre, School of Kinesiology and Health Science, York University, Toronto, Ontario, Canada;
Jacqueline L BeaudryDepartment of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; and.
Hazel HuntCorcept Therapeutics, Menlo Park, California.
Joseph K BelanoffCorcept Therapeutics, Menlo Park, California.
Michael C RiddellMuscle Health Research Centre, School of Kinesiology and Health Science, York University, Toronto, Ontario, Canada; mriddell@yorku.ca.
York University · CACorcept Therapeutics (United States) · USUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe caloric restriction (CR), in a setting of regular physical exercise, may be a stress that sets the stage for adiposity rebound and insulin resistance when the food restriction and exercise stop. In this study, we examined the effect of mifepristone, a glucocorticoid (GC) receptor antagonist, on limiting adipose tissue mass gain and preserving whole body insulin sensitivity following the cessation of daily running and CR. We calorically restricted male Sprague-Dawley rats and provided access to voluntary running wheels for 3 wk followed by locking of the wheels and reintroduction to ad libitum feeding with or without mifepristone (80 mg·kg(-1)·day(-1)) for 1 wk. Cessation of daily running and CR increased HOMA-IR and visceral adipose mass as well as glucose and insulin area under the curve during an oral glucose tolerance test vs. pre-wheel lock exercised rats and sedentary rats (all P < 0.05). Insulin sensitivity and glucose tolerance were preserved and adipose tissue mass gain was attenuated by daily mifepristone treatment during the post-wheel lock period. These findings suggest that following regular exercise and CR there are GC-induced mechanisms that promote adipose tissue mass gain and impaired metabolic control in healthy organisms and that this phenomenon can be inhibited by the GC receptor antagonist mifepristone.

Indexed as

Caloric RestrictionPhysical Conditioning, Animal11-beta-Hydroxysteroid Dehydrogenase Type 1AdiposityAnimalsBlood GlucoseBlotting, WesternBody WeightGluconeogenesisGlucose IntoleranceGlucose Tolerance TestGlycogenGlycogenolysisHormone AntagonistsInsulinInsulin Resistance11-beta-Hydroxysteroid Dehydrogenase Type 1Blood GlucoseGlycogenHormone AntagonistsInsulinMifepristoneReceptors, Glucocorticoidadiposity reboundcaloric restrictionexerciseglucocorticoid antagonismglucose intolerance

Identifiers

PMID27143556
PMCPMC4967147
OpenAlexW2346157220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.